bluebird bio (BLUE) PT Raised to $9 at BofA Securities
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/29/2026
- Wall Street ends higher as Fed holds key rate steady, focus turns to earnings
- SK Hynix shares surge after Q3 profit beats expectations
- Oil prices rise on Yemen fighting, Saudi refinery attack
- Alphabet stock rises as OpenAI plans to buy Google's TPUs
- Wendy's shares surge 16% on $1.4 billion takeover bid by Nelson Peltz’s Trian Fund
Tweet
Share
E-mailGet Alerts BLUE Hot Sheet
Price: $4.97 --0%
Rating Summary:
10 Buy, 19 Hold, 3 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 6 | Down: 11 | New: 6
Rating Summary:
10 Buy, 19 Hold, 3 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 6 | Down: 11 | New: 6
Join SI Premium – FREE
BofA Securities analyst Jason Gerberry raised the price target on bluebird bio (NASDAQ: BLUE) to $9.00 (from $8.00) while maintaining a Neutral rating.
You May Also Be Interested In
- Universal Display (OLED) PT Raised to $95 at Susquehanna
- GE Vernova (GEV) PT Lowered to $1,125 at TD Cowen
- Fortinet (FTNT) PT Lowered to $145 at Jefferies
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
